Upconversion Nanoparticles for photodynamic therapy

Author

Tokatli-Apollon, Amira ; Hyungseok Lee ; El-rifai, Mahmoud ; Punjabi, Amol ; Xiang Wu ; Gang Han

Author_Institution

Med. Sch., Dept. of Biochem. & Mol. Pharmacology, Univ. of Massachusetts, Worcester, MA, USA

fYear

2014

fDate

25-27 April 2014

Firstpage

1

Lastpage

2

Abstract

In order to establish a noninvasive cancer therapy with minimal side effects, low cost, and specific in targeting tumor cells. The team engineered novel and biocompatible Upconversion Nanoparticles (UCNPs) with a calcium fluoride shell α-NaYF4:Yb, Er@CaF2 and conjugated with an FDA approved prodrug 5-Aminolevulinic Acid (ALA). In conjunction with photodynamic therapy (PDT), deep tissue penetration was achieved. UCNPs convert near-infrared light into visible light when excited at ~980nm. Emission of the red light from the UCNPs activate the photosensitizer protoporphyrin (PpIX), causing the production of reactive oxygen species (ROS) causing the death of targeted tumor.

Keywords

calcium compounds; cancer; cellular biophysics; drug delivery systems; drugs; erbium; nanomedicine; nanoparticles; photodynamic therapy; sodium compounds; tumours; two-dimensional spectra; ytterbium; yttrium compounds; NaYF₄:Yb,Er-CaF₂; PDT; biocompatible upconversion nanoparticles; calcium fluoride shell; conjugated FDA approved prodrug 5-aminolevulinic acid; deep tissue penetration; minimal side effects; near-infrared light; noninvasive cancer therapy; photodynamic therapy; photosensitizer protoporphyrin PpIX; reactive oxygen species; red light emission; targeted tumor death; tumor cell targeting; visible light; Cancer; Couplings; Educational institutions; Medical treatment; Nanoparticles; Tumors;

fLanguage

English

Publisher

ieee

Conference_Titel

Bioengineering Conference (NEBEC), 2014 40th Annual Northeast

Conference_Location

Boston, MA

Type

conf

DOI

10.1109/NEBEC.2014.6972959

Filename

6972959